DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Stock Information for DiaMedica Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.
More Recent News About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results